- HIV infection:
- PO 1 tab OD
- Tablet:
- 50mg/600mg/300mg
- Can be taken with or without food
Dolutegravir: INSTI. It inhibits HIV-1 replication by blocking the strand transfer step of viral DNA integration into the host genome.
Abacavir: NRTI (guanosine analog). It inhibits HIV reverse transcriptase by inhibiting viral replication
Lamivudine: NRTI (cytosine analog). It inhibits HIV reverse transcriptase by viral DNA chain termination.
- Hyperlipasemia
- Hyperglycemia
- CK elevated
- Neutropenia
- Insomnia
- LFTs elevated
- Headache
- Fatigue
- Hypersensitivity reaction
- Diarrhea
- Hypercholesterolemia
- Weight gain
- Nasal symptoms
- Cough
- Neuropathy
- Anorexia
- Dizziness
- Hyperamylasemia
- Anxiety
- Cr increase
- Presence of HLA-B*5701 allele
- Previous hypersensitivity reaction to abacavir, dolutegravir or lamivudine
- Moderate or severe hepatic impairment
WARNING
- Hepatitis B exacerbations
- Serious or fatal hypersensitivity reactions have occurred with abacavir-containing products
- Dofetilide
- Elvitegravir/cobicistat/emtricitabine/tenofovir DF
Drug Status
| Availability | Prescription only |
| Pregnancy | Contraindicated |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Triumeq | 50mg/600mg/300mg | Tablet | 30’s | GSK Ltd | GSK Ltd |